Limitations of Regular Human Insulin
- Slow onset of action with subcutaneous injection
- Requires inconvenient administration 30 to 45 min before meal
- Risk of hypoglycemia if meal is delayed
- Does not appropriately match post-prandial hyperglycaemic peak
- Does not allow for good dose titration for ingested carbohydrates
- Duration of action beyond meal absorption
- Increases at higher dosages
- Potential for late post-prandial hypoglycemia
- Contributes to night-time hypoglycemia
Rapid Acting Analogue Insulin - Lispro
- Humalog structure is identical to that of endogenous human insulin except for the reversal of 2 amino acids, lysine and Proline, in the distal part of the B chain.
- Manufactured using non-pathogenic E. coli that has been genetically altered by the addition of the insulin Lispro gene
Compared with Regular Human Insulin, Humalog :
- Is more physiologic time action profile - more closely mirrors the body’s own; more rapid onset, and shorter duration.
- Achieves better glucose control - less post-prandial hyperglycemia, less nocturnal hypoglycemia
- Allows for greater satisfaction - just " Dose and Eat " flexibility means greater patient satisfaction.
Meta-analysis of 8 Studies Shows Humalog® Reduces Severe Hypoglycemic Episodes
Reductions in Postprandial Glucose Lead to Reduced HbA1c with Humalog® in Type 2 Diabetes
Humalog® Improves Diabetes Quality of Life Compared with Regular Human Insulin in Type 2 Diabetes
Last Update: 2 Nov 15